Industry Spotlight: Precidiag
Precidiag is in the process of developing therapeutics to precisely target pathogenic pathways in the gut lumen. Artificial intelligence (AI) is employed to efficiently identify and prioritize the development of both large and small molecule drugs with improved response rates and fewer side effects.
In concert with Massachusetts General Hospital, Precidiag is undertaking a study to investigate the associations of gut microbiota to the symptoms experienced by individuals with ASD.
To find out more visit Precidiag website.